NewGenIVF to buy additional 3% stake in K25.ai at US$250 million valuation
NIVF•Share issuance and Nasdaq compliance
Consideration includes the issuance of about 2,500,000 Class A ordinary shares; total shares are expected to increase to about 5,900,000.
The new share issuance is expected to lift market capitalization above USD 5 million, supporting Nasdaq listing compliance.
NewGenIVF agrees to buy additional K25.ai stake
NewGenIVF entered a definitive agreement to buy an additional 3% of K25.ai at a USD 250 million equity valuation.
Transaction value is set at USD 7.5 million, and the aggregate stake is expected to rise to 13% from 10% on completion.
